NOVARTIS: OVARIAN CANCER DRUG DISAPPOINTS IN TRIAL (AP)
AP – land take concern Novartis AG said weekday it won’t communicate regulators for authorisation to mart a newborn ovarian cancer take after a late-stage effort evidenced disappointing.
AP – land take concern Novartis AG said weekday it won’t communicate regulators for authorisation to mart a newborn ovarian cancer take after a late-stage effort evidenced disappointing.